[1] Amorphous Drugs: Benefits and Challenges, Springer Berlin Heidelberg, New York, NY, 2018.  [2] EPSRC Strateg. Plan (2019) [https://epsrc.ukri.org/about/plans/strategicplan/].  [3] Phys. Rev. B 83 (2011) 134201.  [4] Phys. Rev. B 86 (2012) 104301.  [5] Phys. Status Solidi A 92 (2015) 054201.  [6] Phys. Rev. B 92 (2015) 054201.  [7] J. Appl. Phys. 117 (2015) 015304.  [8] In: C. Massobrio, J. Du, M. Bernasconi, P.S. Salmon (Eds.), Molecular Dynamics Simulationsa of Disordered Materials, Springer International Publishing, 2015, pp. 415–440.  [9] J. Phys. Chem. Lett. 8 (2017) 1645–1650.  [10] Faraday Discuss. 213 (2018) 287-301.  [11] J. Phys. Chem. Lett. 4 (2013) 4241–4246.  [12] J. Phys. Chem. C 119 (2015) 6428–6434.  [13] J. Phys. Chem. C 121 (2017) 23827–23838.  [14] J. Chem. Phys. 149 (2018) 072327.  [15] J. Chem. Phys. 145 (2016) 211927.  [16] Nat. Commun. 8 (2017) 2257.  [17] Chem. Sci. 9 (2018) 8077–8088.  [18] J. Am. Chem. Soc. 137 (2015) 13658–13669.  [19] Proc. Natl. Acad. Sci. 116 (2019) 2009–2014.  [20] Chem. Rev. 116 (2016) 7078–7116.  [21] J. Phys. Chem. Lett. 7 (2016) 2350–2355.  [22] Phys. Rev. B 85 (2012) 174103.  [23] Mol. Simul. 44 (2018) 866–880.  [24] Mol. Pharm. 12 (2015) 1180–1192.  [25] AAPS PharmSciTech 17 (2016) 200–213.  [26] J. Pharm. Pharmacol. 68 (2016) 705–720.  [27] J. Pharm. Pharmacol. 66 (2014) 256–274.  [28] Cryst. Growth Des. 11 (2011) 2662–2679.  [29] Gross Value Added UK ABPI (2019) [https://www.abpi.org.uk/facts-and-figures/uk-pharmaceutical-market/gross-value-added-in-the-uk/].  [30] Pharmaceutical Agents, US5993859A, 1999 [https://patents.google.com/patent/US5993859A/en].  [31] Sci. Rep. 6 (2016) 36934.  [32] Mol. Pharm. 13 (2016) 1937–1946.  [33] Mol. Pharm. 11 (2014) 3123–3132.  [34] J. Pharm. Sci. 99 (2010) 3787–3806.  [35] Eur. J. Pharm. Sci. 49 (2013) 323–332.  [36] J. Chem. Inf. Model. 54 (2014) 3396–3403.  [37] Mol. Pharm. 12 (2015) 3389–3398.  [38] J. Phys. Chem. Lett. 8 (2017) 3434–3439.  [39] Int. J. Pharm. 495 (2015) 312–317.  [40] ArXiv180204364 Cs Stat (2018) [http://arxiv.org/abs/1802.04364].  [41] J. Chem. Phys. 148 (2018) 241709.  [42] J. Chem. Theory Comput. 13 (2017) 1317–1327.  [43] J. Phys. Chem. A 121 (2017) 370–380.  [44] J. Chem. Phys. 149 (2018) 204507.  [45] Phys. Status Solidi A 213 (2016) 329–334.  [46] J. Phys. Chem. Lett. 8 (2017) 1645–1650.  [47] Phys. Rev. B 92 (2015).  [48] Phys. Rev. B 83 (2011).  [49] J. Comput. Chem. 26 (2005) 1701–1718.  [50] J. Comput. Chem. 31 (2010) 671–690.  [51] CHARMM Force Field [http://mackerell.umaryland.edu/charmm_ff.shtml#charmm].  [52] Mol. Pharm. 10 (2013) 4136–4145.  [53] Macromolecules 27 (1994) 7781–7784.  [54] Phys. Rev. Lett. 105 (2010) 135702.  [55] J. Phys. Chem. B 118 (2014) 5608–5614.  [56] Gaussian Processes for Machine Learning, MIT Press, Cambridge, Mass, 2006.  [57] Python Machine Learning, Packt Publishing, 2015.  [58] A Bayesian Deep Learning Classifier, 2019.  [59] ArXiv161201474 Cs Stat (2016) [http://arxiv.org/abs/1612.01474].  [60] The impact of Brexit on the pharmaceutical sector [https://publications.parliament.uk/pa/cm201719/cmselect/cmbeis/382/38202.htm].  [61] A short cut to billion dollar drugs [https://epsrc.ukri.org/newsevents/news/billiondollardrugs/].  [62] Manufacturing Medicines of the Future [https://epsrc.ukri.org/blog/manufacturing-medicines-of-the-future/].  [63] UK Institute to harness disruptive technology to transform drug discovery [https://epsrc.ukri.org/newsevents/news/ukinstitutedrugdiscovery/].
